Gemina Laboratories Ltd. has announced that its patented chemistry for Antibody Immobilization allows for a massive reduction in antibody usage when used in lateral flow assay diagnostic tests. This is a major technical milestone on the LFA format for Gemina. The Antibody Immobilization Platform allows for the reduction of test line antibody requirements by 75% vs. standard physisorption, without impacting limit-of-detection.

Gemina Labs, a client of our Bristol Investor Relations company, is a biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness.

Read the full press release here: Gemina Labs Antibody Immobilization Chemistry Platform Demonstrates Major Lateral Flow Assay Performance Improvement